{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T17:01:25Z","timestamp":1784394085734,"version":"3.55.0"},"reference-count":30,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,11,29]]},"abstract":"<jats:p>Osteogenesis imperfecta (OI) is a generalised connective tissue disorder associated with low bone mass, bone fragility and increased susceptibility to fractures. First-line treatment to improve bone mineral density (BMD) is usually with bisphosphonates but long-term usage has been associated with uncommon complications such as atypical femoral fractures (AFF). Treatment with teriparatide in this situation has been reported with positive outcomes. However, choice of treatment after 2 years of teriparatide has not been well studied or reported. We describe a patient with OI treated with bisphosphonates for 9 years, who then suffered a spontaneous AFF, was subsequently started on teriparatide for 2 years followed by 6 monthly Denosumab. 1 year post-treatment with Denosumab, there was significant improvement in BMD, good fracture healing and no new fractures. This case highlights the potential use of denosumab following 2 years of teriparatide treatment in patients with OI with AFF.<\/jats:p>","DOI":"10.1136\/bcr-2017-221835","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T23:16:22Z","timestamp":1513811782000},"page":"bcr-2017-221835","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Management of atypical femoral fracture in a patient with osteogenesis imperfecta"],"prefix":"10.1136","volume":"2017","author":[{"given":"Jing Yuan","family":"Tan","sequence":"first","affiliation":[{"name":"Endocrinology, National University Singapore Yong Loo Lin School of Medicine, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherng Jye","family":"Seow","sequence":"additional","affiliation":[{"name":"Endocrinology, Tan Tock Seng Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.1","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.2","doi-asserted-by":"crossref","unstructured":"Tournis S , Dede AD . Osteogenesis imperfecta - a clinical update. Metabolism 2017. doi: 10.1016\/j.metabol.2017.06.001. [Epub ahead of print 8 Jun 2017].doi:10.1016\/j.metabol.2017.06.001","DOI":"10.1016\/j.metabol.2017.06.001"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.3","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.36545"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0017"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.5","first-page":"Cd005088","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1620\/tjem.242.115","article-title":"Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta","volume":"242","author":"Uehara","year":"2017","journal-title":"Tohoku J Exp Med"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.8","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.81"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.10","first-page":"324","article-title":"Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays","volume":"60","author":"Brown","year":"2014","journal-title":"Can Fam Physician"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3109\/17453674.2012.729183","article-title":"Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta\u2013a case report","volume":"83","author":"Meier","year":"2012","journal-title":"Acta Orthop"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.12","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.4158\/EP14141.CR","article-title":"Atypical femoral fracture in an osteogenesis imperfecta patient successfully treated with teriparatide","volume":"20","author":"Holm","year":"2014","journal-title":"Endocr Pract"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.13","unstructured":"Etxebarria-Foronda I , Carpintero P . An atypical fracture in male patient with osteogenesis imperfecta. Clin Cases Miner Bone Metab 20152015;12278."},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of teriparatide treatment in adults with osteogenesis imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J Clin Invest"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.15","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1998"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2016-3745","article-title":"Bisphosphonate treatment and the characteristics of femoral fractures in children with osteogenesis imperfecta","volume":"102","author":"Vuorimies","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4195"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-010-9360-5"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.19","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2002.17.11.2038"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.20","doi-asserted-by":"publisher","DOI":"10.2131\/jts.37.617"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.21","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.145.3.527"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.22","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00774-014-0606-6","article-title":"Atypical femoral fracture in a patient treated with denosumab","volume":"33","author":"Khow","year":"2015","journal-title":"J Bone Miner Metab"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","article-title":"Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report","volume":"61","author":"Thompson","year":"2014","journal-title":"Bone"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.25","first-page":"1","article-title":"An atraumatic femoral fracture in a patient with rheumatoid arthritis and osteoporosis treated with denosumab","volume":"2013","author":"Villiers","year":"2013","journal-title":"Case Rep Rheumatol"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.26","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.4158\/EP12367.CR","article-title":"A case of an unusual subtrochanteric fracture in a patient receiving denosumab","volume":"19","author":"Paparodis","year":"2013","journal-title":"Endocr Pract"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/17453674.2013.854668","article-title":"Atypical femoral fractures bilaterally in a patient receiving denosumab","volume":"85","author":"Drampalos","year":"2014","journal-title":"Acta Orthop"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2025082700473336000_2017.dec19_1.bcr-2017-221835.30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2016-3170","article-title":"Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report","volume":"102","author":"Lamy","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-221835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:47:46Z","timestamp":1756280866000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-221835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":30,"alternative-id":["10.1136\/bcr-2017-221835"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-221835","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,20]]}}}